Establishment Labs® Announces Meghan Trainor as Brand Partner Following Her Breast Augmentation with Motiva Implants®
Establishment Labs (NASDAQ: ESTA) has announced a partnership with GRAMMY Award-winner Meghan Trainor, who recently underwent breast augmentation using Motiva Implants®. This partnership follows the US FDA approval of Motiva Implants® in October 2024.
The implants feature the patented SmoothSilk® surface technology, showing a low 0.5% capsular contracture rate and less than 1% device-related complications. Clinical studies report over 97% patient and surgeon satisfaction rates. The technology includes unique features like shape adaptation and enhanced biocompatibility.
Since 2010, over four million Motiva® devices have been delivered in more than 90 countries globally. The company's technologies are supported by over 200 patent applications and more than 100 clinical and scientific studies.
Establishment Labs (NASDAQ: ESTA) ha annunciato una partnership con la vincitrice di un premio GRAMMY Meghan Trainor, che ha recentemente subito un intervento di aumento del seno utilizzando Motiva Implants®. Questa partnership segue l'approvazione da parte della FDA degli Stati Uniti degli impianti Motiva® nell'ottobre 2024.
Gli impianti presentano la tecnologia brevettata SmoothSilk®, mostrando un basso tasso di contrattura capsulare dello 0,5% e meno dell'1% di complicazioni correlate al dispositivo. Gli studi clinici riportano oltre il 97% di soddisfazione tra pazienti e chirurghi. La tecnologia include caratteristiche uniche come l'adattamento della forma e una biocompatibilità migliorata.
Dal 2010, sono stati consegnati oltre quattro milioni di dispositivi Motiva® in più di 90 paesi in tutto il mondo. Le tecnologie dell'azienda sono supportate da oltre 200 domande di brevetto e più di 100 studi clinici e scientifici.
Establishment Labs (NASDAQ: ESTA) ha anunciado una asociación con la ganadora del premio GRAMMY Meghan Trainor, quien recientemente se sometió a un aumento de senos utilizando Motiva Implants®. Esta asociación sigue a la aprobación de la FDA de EE. UU. de los implantes Motiva® en octubre de 2024.
Los implantes cuentan con la tecnología de superficie patentada SmoothSilk®, que muestra una baja tasa de contractura capsular del 0,5% y menos del 1% de complicaciones relacionadas con el dispositivo. Los estudios clínicos informan tasas de satisfacción de más del 97% entre pacientes y cirujanos. La tecnología incluye características únicas como la adaptación de forma y una biocompatibilidad mejorada.
Desde 2010, se han entregado más de cuatro millones de dispositivos Motiva® en más de 90 países en todo el mundo. Las tecnologías de la empresa están respaldadas por más de 200 solicitudes de patentes y más de 100 estudios clínicos y científicos.
Establishment Labs (NASDAQ: ESTA)는 최근 Meghan Trainor와 파트너십을 발표했습니다. 그녀는 최근 Motiva Implants®를 사용하여 유방 확대 수술을 받았습니다. 이 파트너십은 2024년 10월 미국 FDA에서 Motiva Implants®의 승인을 받은 이후 이루어졌습니다.
이 임플란트는 특허받은 SmoothSilk® 표면 기술을 특징으로 하며, 낮은 0.5%의 캡슐 구축 비율과 1% 미만의 장치 관련 합병증을 보여줍니다. 임상 연구에 따르면 환자와 외과의사의 만족도는 97% 이상입니다. 이 기술은 형태 적응 및 향상된 생체적합성과 같은 독특한 기능을 포함합니다.
2010년 이후로, 전 세계 90개국 이상에 걸쳐 400만 개 이상의 Motiva® 장치가 공급되었습니다. 이 회사의 기술은 200개 이상의 특허 출원과 100개 이상의 임상 및 과학 연구에 의해 지원됩니다.
Establishment Labs (NASDAQ: ESTA) a annoncé un partenariat avec la gagnante d'un prix GRAMMY Meghan Trainor, qui a récemment subi une augmentation mammaire en utilisant Motiva Implants®. Ce partenariat fait suite à l'approbation des implants Motiva® par la FDA américaine en octobre 2024.
Les implants présentent la technologie de surface brevetée SmoothSilk®, affichant un faible taux de contracture capsulaire de 0,5 % et moins de 1 % de complications liées au dispositif. Les études cliniques rapportent un taux de satisfaction de plus de 97 % parmi les patients et les chirurgiens. La technologie comprend des caractéristiques uniques telles que l'adaptation de la forme et une biocompatibilité améliorée.
Depuis 2010, plus de quatre millions de dispositifs Motiva® ont été livrés dans plus de 90 pays à travers le monde. Les technologies de l'entreprise sont soutenues par plus de 200 demandes de brevet et plus de 100 études cliniques et scientifiques.
Establishment Labs (NASDAQ: ESTA) hat eine Partnerschaft mit der GRAMMY-Gewinnerin Meghan Trainor angekündigt, die kürzlich eine Brustvergrößerung mit Motiva Implants® durchgeführt hat. Diese Partnerschaft folgt auf die Genehmigung der Motiva Implants® durch die US-amerikanische FDA im Oktober 2024.
Die Implantate verfügen über die patentierte SmoothSilk® Oberflächentechnologie, die eine niedrige Kapselkontraktionsrate von 0,5 % und weniger als 1 % gerätebezogene Komplikationen aufweist. Klinische Studien berichten von über 97 % Zufriedenheit bei Patienten und Chirurgen. Die Technologie umfasst einzigartige Merkmale wie Formanpassung und verbesserte Biokompatibilität.
Seit 2010 wurden weltweit über vier Millionen Motiva®-Geräte in mehr als 90 Ländern ausgeliefert. Die Technologien des Unternehmens werden durch über 200 Patentanmeldungen und mehr als 100 klinische und wissenschaftliche Studien unterstützt.
- FDA approval achieved for US market
- Over 4 million devices delivered globally
- 97% patient and surgeon satisfaction rates
- Low 0.5% capsular contracture rate
- Less than 1% device-related complications
- None.
Insights
Establishment Labs' partnership with Grammy-winning artist Meghan Trainor represents a significant marketing milestone for the company following their October 2024 FDA approval to sell Motiva Implants in the United States. This celebrity endorsement strategically coincides with ESTA's important US market entry phase, potentially accelerating brand awareness among both consumers and medical professionals in the world's largest aesthetic surgery market.
The timing is particularly strategic as ESTA attempts to disrupt an established US breast implant market dominated by legacy players. With over 4 million Motiva devices already delivered globally across 90+ countries, the company has demonstrated product-market fit internationally, but US adoption represents a critical growth vector that could substantially impact their financial trajectory.
From a commercial perspective, this partnership leverages Trainor's 17+ million Instagram followers and broader cultural influence to potentially reduce customer acquisition costs while accelerating market penetration. The breast aesthetics market in the US alone exceeds $1 billion annually, representing ESTA's largest untapped growth opportunity.
Investors should note the impressive clinical data highlighted: less than 1% device-related complications and >97% patient/surgeon satisfaction. These metrics suggest potential for market share gains if they translate to real-world US outcomes. The partnership indicates management's commitment to aggressive marketing strategies rather than relying solely on physician education, potentially accelerating their revenue growth curve in this important new market.
This celebrity partnership represents a calculated shift in ESTA's marketing approach that could fundamentally alter their US market entry dynamics. Most medical device firms rely exclusively on physician-targeted marketing, but securing Trainor creates an unusual direct-to-consumer awareness channel that could drive significant patient demand. The breast augmentation market is highly influenced by patient preference, with consumers increasingly researching options before surgeon consultations.
Trainor's authentic personal story—focusing on post-pregnancy body changes that many women experience—creates powerful relatability that standard clinical marketing cannot achieve. Her emphasis on confidence and body positivity also strategically counters potential stigma associated with breast augmentation, potentially expanding the addressable market beyond traditional demographics.
This partnership leverages several effective marketing principles: celebrity credibility transfer, authentic testimonial (her genuine satisfaction with results), and strategic timing following FDA approval when consumer awareness is critical. The campaign structure featuring the "MotivaUSA.com/Meghan" dedicated landing page demonstrates sophisticated digital marketing integration designed to convert awareness into trackable engagement.
ESTA's approach represents a potential competitive advantage in patient acquisition. Their competitors largely maintain clinical, surgeon-focused marketing approaches despite evidence that patients increasingly drive implant brand selection. This strategy could create meaningful differentiation in a market where products are often viewed as commodities by consumers while potentially generating surgeon trial through patient requests—a pivotal market entry acceleration strategy.
The campaign is the first-of-its-kind partnership and follows the US FDA approval of Motiva Implants®
"Self-confidence and body positivity are so important to me. After losing a bunch of weight and having two kids, I have always struggled loving my breasts because they were never even. I've been dreaming about getting this done for so many years. Once I learned about the recent FDA approval of Motiva Implants®, I knew this was the perfect time for me," Meghan shared. "I did my research, consulted with several plastic surgeons, and chose Motiva Implants® because they offered the look, the smooth silk feel, and the safety I was looking for. There is just such a difference with these new generation implants. I'm absolutely in love with the results — they feel so soft and natural and I'm more confident than ever. I can't wait to get back on stage with so many new outfit choices."
Motiva Implants® represent state-of-the-art innovation in plastic surgery. These implants, available to patients in the US since October 2024, feature the patented SmoothSilk® surface, designed for enhanced biocompatibility and scientifically shown to promote low inflammation1. This surface not only helps the tissue around the implant to stay soft1, but also has led to an industry low
"We could not be more thrilled to partner with Meghan Trainor, an artist who echoes the sentiments we hear from millions of women around the world who choose Motiva® for their breast augmentation," commented Juan José Chacón-Quirós, Founder of Establishment Labs. "It is an exciting time for the organization as we are finally able to bring Motiva® to women in
Since first becoming commercially available in 2010, over four million Motiva® devices have been delivered to plastic and reconstructive surgeons in over 90 countries globally8. The company's technologies and products are covered by over 200 patent applications in 20 separate patent families worldwide and are supported by over 100 clinical and scientific studies and peer reviewed publications9.
"When Meghan came to me, I was excited to offer her Motiva Implants®. These implants are so much better than anything that has been available on the US market. They are designed not only to achieve my patients' aesthetic goals but also to ensure the highest quality and safety, backed by years of research and scientific data that show some of the lowest complication rates," said Payman Danielpour, MD, a board-certified plastic surgeon in
To learn more, visit MotivaUSA.com/Meghan
References:
- Doloff JC, Veiseh O, de Mezerville R, et al. The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans. Nature Biomedical Engineering. 2021. doi:10.1038/s41551-021-00739-4
- Establishment Labs® Holdings Corp. Establishment Labs® Notes Presentation of 4-Year Results from Motiva®
U.S. IDE Study at The Aesthetic Meeting 2024. https://investors.establishmentlabs.com/press-releases/pressreleasesdetails/2024/Establishment-Labs-Notes-Presentation-of-4-Year-Results-from-Motiva-U.S. -IDEStudy-at-The-Aesthetic-Meeting-2024/default.aspx. Published May 2nd, 2024. Accessed May 28th, 2024. - Aitzetmuller-Kleitz ML, Yang S, Wiebinghaus P, Wellenbrock S, Ozturk M, Kuckelhaus M et al. Complication rates after breast surgery with the Motiva SmoothSilk Surface silicone gel implants - A systematic review and meta-analysis. Clin. Med. 2023, 12,1881. doi: 10.3390/jcm12051881
- Establishment Labs, TR-001038: Rheological analysis of silicone filling gels of Motiva Implants® and other brands' silicone filling gels using the BTC-2000. Data on File.
- Establishment Labs, DDD-002: Device Description Document for Sterile Silicone Breast Implants Motiva Implants® Ergonomix® Round SmoothSilk® /SilkSurface®. Data on File.
- Establishment Labs, DDD-001: Device Description Document Sterile Silicone Breast Implants Motiva Implants® Round SmoothSilk® /SilkSurface® Plus. Data on File.
- Caroline Glicksman, Andrew Wolfe, Patricia McGuire, The Study of the Safety and Effectiveness of Motiva SmoothSilk® Silicone Gel-Filled Breast Implants in Patients Undergoing Primary and Revisional Breast Augmentation: Three-Year Clinical Data, Aesthetic Surgery Journal, 2024;, sjae134, https://doi.org/10.1093/asj/sjae134
- Establishment Labs®, Post-Market Surveillance Preliminary Results Q4 2024. Internal Data on File.
- LIS001100: Motiva Publications List of Safety and Performance. Internal Data on File.
Important safety information:
The Motiva SmoothSilk® Round and SmoothSilk Ergonomix® Silicone Gel Breast Implants are indicated for breast augmentation for women of at least 22 years old. Breast augmentation includes primary breast surgery to increase the breast size, as well as revision surgery to correct or improve the result of an original primary breast augmentation surgery (i.e., revision-augmentation). Breast Implant surgery is contraindicated in women with active infection anywhere in their bodies, with existing cancer or pre-cancer of their breast who have not received sufficient treatment for those conditions, or who are currently pregnant or nursing. Adequate studies have not been performed to confirm the safety of breast implant surgery in women with these conditions or under these circumstances; therefore, if you have any of the conditions or circumstances listed above, breast augmentation surgery with implants should not be performed at this time. Failure to take into consideration these contraindications may increase the risks involved with breast implant surgery and have the potential to cause harm. Patients should be advised that key complications have historically been associated with silicone gel breast surgery and implantation of silicone gel breast implants including, but not limited to, capsular contracture, implant removal, reoperation, infection, and rupture. Further, breast implants are not lifetime devices and patients should visit their healthcare professional, as recommended. For more detailed information about the benefits and risks of Motiva SmoothSilk® Round and SmoothSilk Ergonomix® Silicone Gel Breast Implants, please visit: www.motivausa.com or call Motiva at 1-800-924-5072.
The sale and distribution of this device are restricted to users and/or user facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Motiva
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation, and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company's performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company's annual report on Form 10-K filed on March 4, 2024 and discussed in the company's quarterly report on Form 10-Q filed on November 12, 2024, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.
Media Contact
Motiva@EvolveMKD.com
646-517-4220
Investor Relations
rdenhoy@establishmentlabs.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/establishment-labs-announces-meghan-trainor-as-brand-partner-following-her-breast-augmentation-with-motiva-implants-302394850.html
SOURCE Establishment Labs
FAQ
What are the key features of Motiva Implants that ESTA offers?
When did Motiva Implants receive FDA approval for the US market?
How many Motiva devices has ESTA delivered globally since 2010?
What is the clinical success rate of ESTA's Motiva Implants?
